HDAC6 and breast carcinoma: Studies have shown that tamoxifen-resistant T47D (T47D-TAR) cells are sensitive to HDAC6 inhibition by its effect on the Hippo pathway and inhibiting HDAC6 by suppressing YAP expression is considered a potential new strategy for treating tamoxifen-resistant breast cancer.